ArticleVirology journal2008
Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.
Article in Virology journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Bioorthogonal Surface Modification of Measles and Vaccinia Viruses Using Metabolic Azide Reporters.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Article
- Progress in Adenoviral Capsid-Display Vaccines.Biomedicines · 2018Review
- A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors.Viruses · 2016Article
- Development of an Ad5H3 Chimera Using the "Antigen Capsid-Incorporation" Strategy for an Alternative Vaccination Approach.The open virology journal · 2016Article
- Article
- Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.Virology journal · 2015Article
- Exploration of New Sites in Adenovirus Hexon for Foreign Peptides Insertion.The open virology journal · 2015Article
- Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection.PLoS neglected tropical diseases · 2014Article
- A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.Virology journal · 2014Article
- Review
- Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine.Human gene therapy · 2013Article
- Using multivalent adenoviral vectors for HIV vaccination.PloS one · 2013Article
- Article
- Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon.PloS one · 2012Article
- Unnatural amino acid incorporation onto adenoviral (Ad) coat proteins facilitates chemoselective modification and retargeting of Ad type 5 vectors.Journal of virology · 2011Article
- Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.Molecular pharmaceutics · 2011Review
- Current progress in the development of a prophylactic vaccine for HIV-1.Drug design, development and therapy · 2010Review
- Chemoselective attachment of small molecule effector functionality to human adenoviruses facilitates gene delivery to cancer cells.Journal of the American Chemical Society · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Despite the many potential advantages of Ad vectors for vaccine application, the full utility of current Ad vaccines may be limited by the host anti-vector immune response. Direct incorporation of antigens into the adenovirus capsid offers a new and exciting approach for vaccination strategies; this strategy exploits the inherent antigenicity of the Ad vector. Critical to exploiting Ad in this new context is the placement of antigenic epitopes within the major Ad capsid protein, hexon. In our current study we illustrate that we have the capability to place a range of antigenic epitopes within Ad5 capsid protein hexon hypervariable regions (HVRs) 2 or 5, thus producing viable Ad virions. Our data define the maximal incorporation size at HVR2 or HVR5 as it relates to identical antigenic epitopes. In addition, this data suggests that Ad5 HVR5 is more permissive to a range of insertions. Most importantly, repeated administration of our hexon-modified viruses resulted in a secondary anti-antigen response, whereas minimal secondary effect was present after administration of Ad5 control. Our study describes antigen placement and optimization within the context of the capsid incorporation approach of Ad vaccine employment, thereby broadening this new methodology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.